Thelansis

  Pseudoxanthoma elasticum (PXE) is an inherited metabolic disorder due to  ABCC6  gene mutations. It is characterized by progressive calcification and fragmentation of elastic fibers in the skin, retina, and arterial wall. Despite calcium accumulation in the arteries of PXE patients, functional consequences remain unknown. According to the literature review conducted by Thelansis, the prevalence of PXE, estimated to be 1 in 50,000, would imply that there are ~8,000–10,000 PXE patients in the United States. With the same global prevalence, there could be as many as 160,000 to 200,000 patients affected with PXE worldwide. Thelansis’s “Pseudoxanthoma Elasticum (PXE) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market for...